Navigation Links
Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Date:11/3/2008

THOUSAND OAKS, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will hold its Business Review Meeting on Friday, Nov. 7, 2008 at the Millennium Broadway Hotel, 145 West 44th Street, New York City, beginning at 8 a.m. Eastern Time. Participating in the meeting will be Kevin Sharer, chairman and CEO, Roger M. Perlmutter, M.D., Ph.D., executive vice president, Research and Development, George Morrow, executive vice president, Global Commercial Operations, Robert Bradway, executive vice president and CFO, and other members of Amgen's senior management team.

Live video of the meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's Web site, http://www.amgen.com, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay 72 hours after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
4. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
7. Amgen Announces Webcast of 2008 Third Quarter Financial Results
8. Amgens Third Quarter 2008 Adjusted Earnings Per Share Increased 14 Percent to $1.23
9. Call for Applications: The Amgen Award for Science Teaching Excellence
10. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , December 5, 2016 ... "Cell Expansion Market, by Products (Consumable, Instruments, Automated ... (Regenerative Medicine and Stem Cell Research, Cancer, and ... Institutes, Cell Banks) - Global Revenue, Trends, Growth, ... Scalar Market Research, the global cell expansion market ...
(Date:12/5/2016)... 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the ... and Safety Monitoring Board (DSMB) for the Company,s ... (CVD) patients has completed a second planned safety ... as planned without any modifications. The DSMB reviewed ... or efficacy concerns were identified. The DSMB will ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/5/2016)... 5, 2016 The U.S. Biotechnology ... $108 billion of revenue and some $890 billion of ... on global biopharmaceuticals, and this figure is expected to ... lined up these four equities for assessment: Northwest Biotherapeutics ... (NASDAQ: ACAD ), Acorda Therapeutics Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... Systems, Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & ... intelligence provider visiongain offers comprehensive analysis of ... that this market will generate revenues of $17.98 billion ... Systems acquired DVTEL Inc, a leader in software and ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):